NDC properties for NDC 9 63323-305
NDC item 63323030501
| NDC 9 | 63323-305 |
|---|---|
| NDC 10 | 63323-305-01 |
| NDC Item | 63323030501 |
| packaging | 2 mL in 1 VIAL, MULTI-DOSE |
| ANDA | ANDA065122 |
| FDA SPL set id | 773621 |
| Labeler | Fresenius Kabi USA, LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2004-11-30 |
| Marketing status | ACTIVE |
NDC item 63323030502
| NDC 9 | 63323-305 |
|---|---|
| NDC 10 | 63323-305-02 |
| NDC Item | 63323030502 |
| packaging | 25 VIAL, MULTI-DOSE in 1 TRAY (63323-305-02) / 2 mL in 1 VIAL, MULTI-DOSE (63323-305-01) |
| ANDA | ANDA065122 |
| FDA SPL set id | 773621 |
| Labeler | Fresenius Kabi USA, LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2004-11-30 |
| Marketing status | ACTIVE |
NDC item 68083025301
| NDC 9 | 68083-253 |
|---|---|
| NDC 10 | 68083-253-01 |
| NDC Item | 68083025301 |
| packaging | 2 mL in 1 VIAL, MULTI-DOSE |
| ANDA | ANDA209621 |
| FDA SPL set id | 699468 |
| Labeler | Gland Pharma Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-11 |
| Marketing status | ACTIVE |
NDC item 68083025325
| NDC 9 | 68083-253 |
|---|---|
| NDC 10 | 68083-253-25 |
| NDC Item | 68083025325 |
| packaging | 25 VIAL, MULTI-DOSE in 1 CARTON (68083-253-25) / 2 mL in 1 VIAL, MULTI-DOSE (68083-253-01) |
| ANDA | ANDA209621 |
| FDA SPL set id | 699468 |
| Labeler | Gland Pharma Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-11 |
| Marketing status | ACTIVE |